Diabetes

Sun Pharmaceuticals issued a voluntary recall of 1 lot of its metformin hydrochloride for extended-release (ER) oral suspension (Riomet ER), 500 mg per 5 mL.

In a post-hoc analysis, researchers reported the effects of semaglutide on kidney function in patients with type 2 diabetes.

The study marks the first pharmacoepigenetic study in diabetes evaluating epigenetic factors as biomarkers to predict a drug’s effects on an individual.

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

The MiniMed 770G system (Medtronic) is approved for use by individuals aged 2 to 6 with type 1 diabetes.

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

The removal of the boxed warning from canagliflozin was based on the FDA’s review of new data from 3 clinical trials.

Individuals with metabolic syndrome who were hospitalized for COVID-19 were more likely to experience worse outcomes.

Bayshore Pharmaceuticals issued a voluntary recall of 2 lots of its extended-release metformin products due to high levels of NDMA.

Lilly is committed to helping people who face high out-of-pocket costs for insulin by offering a broad suite of affordable solutions.

Youth with diabetes who are involved in the decision to start continuous glucose monitoring reported consistent use 2 months after starting.

Joshua Miller, MD MPH and medical director of diabetes care for Stony Brook Medicine, discusses continuous glucose monitoring (CGM) technology, which the FDA has authorized for use in hospitals amid the COVID-19 pandemic.

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Unemployment rates compounded with high medical costs plague the diabetes community during the coronavirus disease 2019 (COVID-19) pandemic.

“I just hope that pharmacists’ judgment can soon be a contributing factor in pharmacotherapy decisions made by PBMs and insurance companies.”

In this episode of Over the Counter, 2 experts on diabetes management and care discuss the effect COVID-19 is having on individuals with diabetes and the ways that the health care system is responding.

Individuals with type 2 diabetes who exhibit extreme sleep duration hours may have a higher risk of death than individuals without diabetes.

Type 2 diabetes risk prediction is improved by observing changes in gut bacteria, a study finds.

Xeris Pharmaceuticals’ new glucagon injection (Gvoke HypoPen), a ready-to-use glucagon formulation in a premixed autoinjector, is now available by prescription.

Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.

The CDC has identified the pharmacy sector as a key partner in offering its lifestyle change-based program for patients with high risk for type 2 diabetes.

The first and only one of its kind, metoclopramide nasal spray offers relief to often debilitating symptoms of the gastrointestinal disease.

In response to the study, the NYC Department of Health is pursuing large-scale implementation of this approach, targeting diabetes hot spots across the city through public health messaging, mailed print materials, and Care Calls.

“We know that if we don’t address these potential difficulties before they occur, the burden to families can be devastating and the health care costs are tremendous.”